live SARS-CoV-2

[키워드] abnormal change abnormal changes Academy administration adverse event adverse events Adverse reaction Adverse reactions All participant All participants analyses Analysis Anti-RBD IgG anti-SARS-CoV-2 Antibody titre assigned baseline block Block randomisation caused cellular immune responses China Chinese clinical testing conducted convalescent patient Convalescent patients COVID-19 pandemic development domain dose dose-escalation doses double-blind effective vaccine Effective vaccines eligible participant ELISA ELISPOT ENCODE enrolled enzyme enzyme-linked immunospot expected exploratory Fever first vaccination FIVE foundation grade 3 group groups highest hospital humoral humoral immune responses Humoral response humoral responses IFN-γ IL-2 immune immune response immune responses immunogenicity incidence individual Intramuscular injection investigators Laboratory laboratory analyses Laboratory test Laboratory tests live SARS-CoV-2 lowest majority Medical Science Medical Sciences Mild moderate mRNA vaccine natural neutralisation assays Neutralising Antibodies neutralising antibody observation outcome participant Participants peaked Phase 1 phase 1 trial Placebo placebo group placebo-controlled Primary outcome pseudovirus randomised Randomly RBD RBD IgG RBD-specific IgG receive Registered reported research and development resolved Safe Safety safety analyses safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-specific T-cell response SARS-CoV-2-specific T-cell responses Science screened second dose second vaccination secondary outcome Serious Adverse Event Serious Adverse Events Seven significantly Specific Specific T-cell response Spike protein Support systemic adverse event T-cell Response T-cell responses the placebo group the SARS-CoV-2 titre titres Tolerability treatment allocation Trial vaccination Vaccine vaccine dose vaccine doses were assessed were given with COVID-19 Zhejiang
[DOI] 10.1016/S2666-5247(21)00280-9 PMC 바로가기 [Article Type] Clinical Trial